Healthcare Industry News: abdominal aortic aneurysm
News Release - August 25, 2009
Medical Industry Veteran Bob Katz to Lead Newly Established PinPointe USA, Inc. as CEOCHICO, Calif.--(HSMN NewsFeed)--PinPointe USA Inc., an emerging medical device company developing advanced laser-based technology and products for the treatment of onychomycosis (commonly known as toenail fungus), today announced the appointment of Bob H. Katz as President and CEO, and as a member of its Board of Directors.
“We are excited to have Bob join the team and lead our company as we accelerate commercialization of our proprietary laser treatment technology,” said John Strisower, Founder and Chairman of the Board of PinPointe USA. “His breadth of experience in bringing a broad range of medical technologies and products to market will add significant value to the company.”
Mr. Katz brings twenty-five years of medical device development experience to PinPointe USA, including the development of numerous therapeutic and interventional technologies in a wide range of applications. Prior to joining PinPointe USA, he was President & CEO of Aptus Endosystems, Inc. a venture-capital backed developer of implantable stent-graft technology for abdominal aortic aneurysm repair. Mr. Katz previously held executive management positions for other medical device companies including President of ZOLL Circulation, which developed and commercialized breakthrough technology for the treatment of out of hospital sudden cardiac arrest and Symphonix Devices, a venture capital backed start-up which developed and commercialized novel implantable technology for the hearing impaired.
The addition of Mr. Katz to the PinPointe USA team is the latest in a series of positive developments for the company, which announced in June the launch of a major North American multi-center clinical trial to evaluate the PinPointe FootLaser, the company’s flagship product for the treatment of onychomycosis and the announcement in February of the company’s receipt of a CE Mark, and in July for TGA approval, for the PinPointe FootLaser opening the way for commercial product launch for the treatment of onychomycosis throughout the European Union and Australia.
“This is a very exciting time for the company. We are embarking upon multiple initiatives to build our franchise and establish PinPointe USA as the global leader in onychomycosis treatment,” added Mr. Katz.
Onychomycosis is a fungal infection of the nail (toenail and fingernail). It is the most common of the diseases affecting the nail and constitutes about a half of all nail abnormalities. The prevalence of onychomycosis is about 8 - 10% in the adult general population. The causative pathogens of onychomycosis include dermatophytes, candida, and non-dermatophytic molds. Treatment of onychomycosis is challenging because the infection is typically embedded within the nail and is difficult to reach. As a result, full removal of symptoms can be very slow and may take a year or more. Current treatment therapies for onychomycosis, including pharmaceuticals, represent approximately a $1Billion market, although effectiveness of current treatment regimes is typically less than 10% and may carry significant side effects.
About PinPointe USA, Inc.
Founded in 2004, PinPointe USA, Inc. is a privately held, emerging medical technology with headquarters in Chico, California. PinPointe USA has assembled a world-class group of scientists, academic thought leaders and leading clinical practitioners from around the world to bring to market a new generation of laser technology to address onychomycosis (toenail fungus) and other footcare therapies. For more information, please visit us at www.PinPointeUSA.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.